The rare disease drugs are regulated by the FDA. Recently, in the market there are three new drugs approved by the FDA for the treatment of two new types of rare diseases including non-Hodgkin lymphomas, and Fabry disease. The new drugs are Mogamulizumab-kpkc injection, Lanadelumab-flyo, and migalastat. Recently, the United States regulators registered COVID-19 as rare disease treatment. For this FDA grant an experimental medicine known as remdeivir for the treatment of coronavirus disease. With the continuously rising COVID-19 cases in the United States region, the health agency's made decisions to provide remdesivir at a lower price (if it will be approved).

According to the report, Increase in investment from the manufacturers of the leading drug across the globe to developing therapies, invest more in research and focused on offering innovative solutions. Which can bring high potential to offer a solution which impacted on rare diseases. The company is providing drugs to provide patients which includes emerging markets, with advance healthcare. is one of the primary growth factors for the market. Rising Awareness among Consumers is also expected to contribute significantly to the Rare Disease Drug market. Overall, Hospitals applications of Rare Disease Drug, and the growing awareness of them, is what makes this segment of the industry important to its overall growth. The Disease, such as Oncologic Diseases, is boosting the Rare Disease Drug market. Additionally, the rising demand from SMEs and various industry verticals, macro-economic growth are the prime factors driving the growth of the market.The Form, such as Tablet, is boosting the Rare Disease Drug market. Additionally, the rising demand from SMEs and various industry verticals, macro-economic growth are the prime factors driving the growth of the market.The Distribution Channel, such as Pharmacies, is boosting the Rare Disease Drug market. Additionally, the rising demand from SMEs and various industry verticals, macro-economic growth are the prime factors driving the growth of the market.The Indication, such as Non-Hodgkin Lymphoma, is boosting the Rare Disease Drug market. Additionally, the rising demand from SMEs and various industry verticals, macro-economic growth are the prime factors driving the growth of the market.

New technologies and major shifts in the industry will be game-changing factors that all players have to react now in order to maintain strong positions in the future. As many industry experts agree that significant changes are ahead. AMA’s Analyst on the Global Rare Disease Drug market identified that the demand is rising in many different parts of the world as "Development in Drug Manufacturing Countries ". Furthermore, some recent industry insights like "In August 2019, Critical path Institute and advocacy organization national organization revealed its new data and analytics platform for rare disorders. This platform is having multiple sources including clinical trials, observational studies, real-time data, and others." which is constantly making the industry very dynamic.

The report provides an in-depth analysis and forecast about the industry covering the following key features:
o Industry outlook including current and future market trends, drivers, restraints, and emerging technologies
o Analyses the Global Rare Disease Drug market according to Type, Application, and regions
o Analyzes the top 10 players in terms of market reach, business strategy, and business focus
o Provides stakeholders’ insights and key drivers & trends of the market

**The market is valued based on weighted average selling price (WASP) and includes any applicable taxes on manufacturers. All currency conversions used in the creation of this report have been calculated using constant annual average 2023 currency rates.

Market Size Estimation
In market engineering method, both top-down and bottom-up approaches have been used, along with various data triangulation process, to predict and validate the market size of the Rare Disease Drug market and other related sub-markets covered in the study.

o Key & emerging players in the market have been observed through secondary research.
o The industry’s supply chain and overall market size, in terms of value, have been derived through primary and secondary research processes.
o All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Data Triangulation
The overall Rare Disease Drug market size is calculated using market estimation process, the Rare Disease Drug market was further split into various segments and sub-segments. To complete the overall market engineering and arriving at the exact statistics for all segments and sub-segments, the market breakdown and data triangulation procedures have been utilized, wherever applicable. The data have been triangulated by studying various influencing factors and trends identified from both demand and supply sides of various applications involved in the study. Along with this, the Global Rare Disease Drug market size has been validated using both top-down and bottom-up approaches.